Funding for this research was provided by:
National Health and Medical Research Council (APP1092547)
Received: 24 November 2020
Accepted: 11 April 2021
First Online: 26 April 2021
: Approval was obtained from the following Human Research Ethics Committees: Justice Health & Forensic Mental Health Network (G621/13); Corrective Services NSW (qualitative sub-study approval on April 5, 2016); and Aboriginal Health and Medical Research Council of NSW (1253/17) and UNSW Sydney (HC15645).
: Not applicable.
: JR and LL have nothing to declare. CT has received speaker fees from AbbVie and Gilead Sciences and research funding from Merck.